Compare Novartis AG (NVS) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Southern Copper Corp — how do they compare? Novartis AG trades at $139.46 (market cap $262.64B), while Southern Copper Corp trades at $209 (market cap $176.10B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | SCCO | |
|---|---|---|
Market Cap | $262.64B | $176.10B |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $219.70 |
52-Week Low | $121.80 | $102.10 |
Enterprise Value | $303.97B | $177.39B |
Dividend Yield | 3.44% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Southern Copper (SCCO) trades at $208.56, up 4.93% with strong bullish technical signals and positive earnings momentum. The company demonstrates robust fundamentals with 2025 revenue of $13.42B, net income margin of 35.87%, and consistent earnings beats. Recent news highlights copper's role in AI infrastructure demand, with SCCO benefiting from rising metal prices and a $20.5B investment plan for production growth.
SCCO presents growth potential from copper demand trends but trades at premium valuations (P/E 31.29) above analyst consensus target of $154.58. Key risks include production declines and execution challenges on expansion projects. Institutional buying activity suggests confidence in long-term prospects despite mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
